Related Experiment Video
Updated: Jan 13, 2026
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
A Novel TLR4 Inhibitor DB03476 Rescued Renal Inflammation in Acute Kidney Injury Model
Yi-Fan Zhang1, Yu-Xuan Ma1, Shi-Jie Wei2
1Department of Urology, Fourth Military Medical University, Xi'an 710032, China.
Abstract:
Acute kidney injury (AKI) is a critical clinical syndrome characterized by a rapid decline in renal function, frequently resulting from ischemia, nephrotoxicity, or sepsis. It represents a major global health burden due to its high morbidity and mortality and its strong association with progression to chronic kidney disease. In this study, we identified a novel small-molecule TLR4 inhibitor, DB03476, via structure-based virtual screening targeting the intracellular TIR domain of murine Tlr4. Molecular dynamics simulations confirmed that DB03476 stabilizes Tlr4 without altering its global conformation. In a murine ischemia-reperfusion-induced AKI model, DB03476 administration significantly attenuated renal inflammation, macrophage infiltration, and apoptosis and suppressed the TLR4/MyD88/NF-κB pathway. Moreover, DB03476 exhibited cross-species efficacy by binding conserved residues in human TLR4 with high affinity. Functional validation using human kidney organoids confirmed its protective effects against inflammatory challenge. These results demonstrate DB03476 as a promising therapeutic agent for AKI through selective inhibition of TLR4-mediated inflammatory responses.
Insights
Researchers discovered DB03476, a new drug that inhibits Toll-like receptor 4 (TLR4). This compound shows promise in treating acute kidney injury (AKI) by reducing inflammation and protecting kidney function.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Acute kidney injury (AKI) is a significant clinical problem with high mortality and morbidity.
- AKI is linked to chronic kidney disease progression and involves inflammatory pathways.
- Toll-like receptor 4 (TLR4) plays a key role in mediating inflammatory responses in AKI.
Purpose of the Study:
- To identify and characterize a novel small-molecule inhibitor of TLR4.
- To evaluate the therapeutic potential of the identified inhibitor in an AKI model.
- To investigate the mechanism of action of the TLR4 inhibitor.
Main Methods:
- Structure-based virtual screening was employed to identify potential TLR4 inhibitors.
- Molecular dynamics simulations were used to assess inhibitor binding and stability.
- A murine model of ischemia-reperfusion-induced AKI was utilized for in vivo testing.
- Human kidney organoids were used for cross-species validation.
Main Results:
- DB03476, a novel small-molecule TLR4 inhibitor, was identified.
- DB03476 significantly reduced renal inflammation, macrophage infiltration, and apoptosis in an AKI model.
- The compound suppressed the TLR4/MyD88/NF-κB signaling pathway.
- DB03476 demonstrated cross-species efficacy and protective effects in human kidney organoids.
Conclusions:
- DB03476 is a promising therapeutic candidate for AKI.
- The drug selectively inhibits TLR4-mediated inflammatory responses.
- DB03476 offers a potential new treatment strategy for acute kidney injury.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:22Acute Kidney Injury I: Introduction
01:29Acute Kidney Injury II: Pathophysiology
01:20Acute Kidney Injury V: Interprofessional Care
01:25Antihypertensive Drugs: Direct Renin Inhibitors